BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/13/2022 8:46:12 AM | Browse: 450 | Download: 1202
 |
Received |
|
2021-10-27 16:12 |
|
Peer-Review Started |
|
2021-10-27 16:14 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-12-13 03:54 |
|
Revised |
|
2022-01-20 03:48 |
|
Second Decision |
|
2022-03-25 06:34 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2022-03-26 21:48 |
|
Articles in Press |
|
2022-03-26 21:48 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2022-04-19 09:13 |
|
Publish the Manuscript Online |
|
2022-05-13 08:46 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Opinion Review |
| Article Title |
Emerging role of biosimilars in the clinical care of inflammatory bowel disease patients
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Hala Najeeb, Farah Yasmin and Salim Surani |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Salim Surani, FACP, FCCP, MD, MSc, Doctor, Doctor, Professor, Department of Medicine, Texas A&M University, 400 Bizzell St, College Station, TX 77843, United States. srsurani@hotmail.com |
| Key Words |
Inflammatory bowel disease; Biosimilars; Anti-tumor necrosis factor; Infliximab; Adalimumab; Ulcerative colitis; Chrons disease |
| Core Tip |
There is limited evidence on the safety and use of biosimilars other than Infliximab. This review explores the role of biosimilars in an era of anti-tumor necrosis factor-α drug as a treatment option for inflammatory bowel disease. The approval of biosimilars by the Food and Drug Administration or European Medicines Agency based on their similarity and functionality to the reference product has raised concerns regarding its efficacy. Many remain hesitant in recommending biosimilars as a viable treatment option, despite its promise of reducing long-term costs. This originates from the lack of clinical trials of biosimilars. Although no serious adverse events have been reported with biosimilars, conclusions cannot be drawn without sufficient empirical evidence. |
| Publish Date |
2022-05-13 08:46 |
| Citation |
Najeeb H, Yasmin F, Surani S. Emerging role of biosimilars in the clinical care of inflammatory bowel disease patients. World J Clin Cases 2022; 10(14): 4327-4333 |
| URL |
https://www.wjgnet.com/2307-8960/full/v10/i14/4327.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v10.i14.4327 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
